Jardiance Tablet, Film Coated
Product Images NDC 50090-4492

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Jardiance (NDC 50090-4492). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Jardiance 01

FDA Label Image

Jardiance 02

This appears to be a list of different drugs with their respective dosages. Some of the drugs are for anti-diabetic purposes while others are for different conditions such as high blood pressure or high cholesterol. There is also a section at the bottom which appears to be documenting some sort of study or experiment, however, it is not clear what is being measured or compared.*

FDA Label Image

Jardiance 03

This text appears to be a list of different drugs and their dosages. The drugs in this list include antidiabetic drugs, oral contraceptives, and other medications. It also mentions the frequency of dosage for each drug. However, the text does not provide any context or information about what these drugs are used for and how they may affect the body. There is also a section on geometric mean ratio with different percentages.*

FDA Label Image

Jardiance 04

This is a description of changes in HbA1C (%) over time in a clinical trial with three groups: a placebo group (N=185), a group treated with Empagificzin 10 mg (N=206), and a group treated with Empagificzin 25 mg (N=202). The graph shows the mean change from baseline in the HbA1C levels at weeks 6, 12, 18, and 24. The mean change from baseline is adjusted for baseline HbA1c, geographical region, and oGFR at baseline.*

FDA Label Image

Jardiance 05

This is a description of the mean change in HbA1c (%) from baseline in patients treated with Glimepiride + Metformin (N=700) or Empagliiflozin 25 mg + Metformin (N=693) over a 52-week period. The chart shows the mean change at 4, 12, 28, 40, and 52 weeks for both treatments. The data are adjusted for baseline HbA1c, geographical region, and eGFR at baseline.*

FDA Label Image

Jardiance 06

This data appears to be the result of a clinical trial or study involving patients and a drug called Empaglifiozin. There are columns showing the number of patients who experienced an "event" (the specific definition of which is not provided) as well as the number of subjects at risk for each drug group (Placebo and Empaglifiozin). However, without additional context or information about the purpose of the study, it is difficult to provide a more detailed description of the data.*

FDA Label Image

Jardiance 07

FDA Label Image

Jardiance 08

FDA Label Image

Label Image (Lbl500904492)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.